CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Osteoporosis - treatment (and prevention of fragility fractures) - Management
NICE review
The CKS topic on Osteoporosis — treatment (and prevention of fragility fractures) is currently being updated and will be published when the National Institute for Health and Clinical Excellence has reviewed its guidance on Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.
For information on the assessment and management of people taking corticosteroids who have osteoporosis, or who at risk of osteoporosis, see the CKS topic on Osteoporosis - preventing steroid-induced.
For information on the identification and management of the risk of falling in older people, see the CKS topic on Falls - risk assessment.
© NHS Institute for Innovation and Improvement